肝病治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球肝病治療市場規模達245億美元，預計2034年將以7.7%的複合年成長率成長，達到504億美元。隨著全球肝臟相關疾病的發生率持續上升，該市場正經歷強勁成長。推動這一成長的主要動力之一是全球各年齡層肝病發病率的上升。由於遺傳、環境和生活方式等多種因素的影響，慢性和急性肝病正變得越來越普遍。

人口老化是導致肝病治療需求不斷增加的另一個重要因素。隨著人們壽命的延長，與年齡相關的健康問題（包括肝功能障礙）也變得越來越普遍。由於長期暴露於酒精、處方藥和代謝紊亂等因素，老年人通常面臨更高的慢性肝病風險。因此，醫療保健產業對專門針對老年患者肝病的治療方案的需求日益成長。

醫療技術的創新也在支撐市場成長方面發揮了重要作用。診斷工具的進步使得早期發現和及時介入成為可能，這對於改善患者預後至關重要。能夠早期識別肝臟疾病的技術正變得越來越普及和可靠，推動了對有效治療的需求。此外，藥物研發領域的持續研究正在催生出旨在更有效地治療複雜肝臟疾病的先進治療配方。這些改進正在促進更廣泛的治療方法的採用，並有助於擴大市場規模。

按產品分類，抗病毒藥物成為表現最佳的細分市場，2024 年的市場規模達 97 億美元。由於病毒性肝炎（尤其是乙肝和丙肝）的廣泛傳播，該細分市場佔據主導地位，而病毒性肝炎仍然是導致慢性肝損傷及其併發症的主要原因之一。

直接抗病毒藥物 (DAA) 憑藉其高治癒率和更少的副作用，顯著改變了治療模式。這些現代療法不僅療效較佳，而且由於療程較短，患者較容易完成治療。療效和安全性較高的新一代抗病毒藥物的上市加速了全球應用，尤其是在感染負擔較重的地區。這些藥物在改善臨床療效方面已得到證實，這使得該領域繼續成為整體市場收入的主要貢獻者。

就疾病類型而言，肝病治療市場可分為肝炎、自體免疫疾病、非酒精性脂肪肝病 (NAFLD)、癌症、遺傳性疾病和其他類別。其中，肝炎領域佔據主導地位，2024 年的市佔率高達 47.4%。這主要是由於B型肝炎和C肝感染在全球範圍內持續存在，亟需有效的醫療解決方案。

持續的藥物創新使治療更加便利高效，配方改進，療程更短、更安全。現代肝炎治療簡化了給藥方案，提高了治癒率，從而提高了患者的依從性。此外，持續研發功能性療法，確保肝炎領域在更廣泛的治療市場中保持領先地位。

依性別分類，市場分為男性和女性兩類。 2024年，男性人口占主導地位，預期複合年成長率為7.2%。這趨勢的促進因素是男性肝病發生率高於女性。研究表明，男性更容易被診斷出患有慢性肝病，包括酒精性肝病、非酒精性脂肪肝（NAFLD）和肝炎。

這種性別差異也與生理和荷爾蒙水平的差異有關。雌激素被認為對肝臟組織具有保護作用，使停經前女性不太可能出現嚴重的肝損傷。另一方面，男性更容易從脂肪肝發展為更嚴重的疾病，例如脂肪肝和肝硬化，這增加了這一人群對醫療干預的需求。

從地區來看，美國是全球收入的最大貢獻者。美國市場規模在2021年為75億美元，2022年為78億美元，2023年為81億美元，2024年達85億美元。這種持續成長反映了肝臟相關健康問題的日益增多，尤其是非酒精性脂肪性肝病（NAFLD）及其更嚴重的類型—非酒精性脂肪性肝炎（NASH）。造成這現象的因素包括肥胖激增、久坐不動的生活方式以及相關的代謝紊亂。

美國的醫療保健體系透過公共和私人保險計劃支持早期診斷和高成本專科治療，這有助於推動市場持續擴張。認知度的提高、廣泛的篩檢工作以及醫療基礎設施的改善，都有助於美國保持領先地位。

在全球範圍內，競爭格局由大型跨國公司、區域性公司和新興企業組成。約45%至50%的市佔率由四家領先公司佔據，這些公司正積極透過合作、收購和推出創新療法來擴大市場佔有率。這些公司正在大力投資研發，以滿足尚未滿足的臨床需求並改善患者治療效果，從而在這個快速發展的行業中佔據戰略優勢。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 肝病盛行率不斷上升
    • 診斷技術的進步
    • 久坐的生活方式、不良飲食和飲酒現象增多
  • 產業陷阱與挑戰
    • 治療費用高昂，尤其是生物製劑
    • 某些藥物的副作用和療效有限
  • 市場機會
    • 非酒精性脂肪性肝炎 (NASH) 和肝癌的強大研發管道
    • 新興市場的擴張
• 成長潛力分析
• 監管格局
• 管道分析
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與協作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：按產品，2021 - 2034 年

• 主要趨勢
• 抗病毒藥物
• 疫苗
• 化療
• 標靶治療
• 免疫抑制劑
• 免疫球蛋白
• 皮質類固醇
• 其他產品

第6章：市場估計與預測：依疾病類型，2021 - 2034 年

• 主要趨勢
• 肝炎
• 自體免疫疾病
• 非酒精性脂肪肝（NAFLD）
• 癌症
• 遺傳性疾病
• 其他疾病類型

第7章：市場估計與預測：依性別，2021 - 2034 年

• 主要趨勢
• 男性
• 女性

第8章：市場估計與預測：按管理路線，2021 - 2034 年

• 主要趨勢
• 口服
• 腸外

第9章：市場估計與預測：依最終用途，2021 - 2034 年

• 主要趨勢
• 醫院和診所
• 門診手術中心
• 其他最終用途

第10章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：公司簡介

• Amgen
• AbbVie
• Bristol-Myers Squibb
• Bayer
• GSK plc
• Gilead Sciences
• Hoffmann-La Roche
• Intercept Pharmaceuticals
• Johnson & Johnson Services
• Merck & Co.
• Novartis
• Pfizer
• Sanofi
• Takeda Pharmaceutical Company Limited
• Zydus Lifesciences

The Global Liver Disease Therapeutics Market was valued at USD 24.5 billion in 2024 and is estimated to grow at a CAGR of 7.7% to reach USD 50.4 billion by 2034. The market is witnessing robust growth as the prevalence of liver-related health conditions continues to rise worldwide. One of the primary forces fueling this growth is the increasing global incidence of liver diseases across all age groups. Liver conditions, both chronic and acute, are becoming more widespread due to a combination of genetic, environmental, and lifestyle-related factors.

An aging population is another important factor contributing to the expanding demand for liver disease treatments. As people live longer, age-related health issues, including liver dysfunction, are becoming more common. Elderly individuals often face a higher risk of chronic liver problems due to prolonged exposure to factors such as alcohol consumption, use of prescription medications, and metabolic disorders. As a result, the healthcare industry is seeing a greater need for therapeutic options that specifically address liver diseases in older patients.

Innovations in medical technology have also played a significant role in supporting market growth. Advancements in diagnostic tools have enabled early detection and timely intervention, which are critical for improving patient outcomes. Technologies that allow for early-stage identification of liver disorders are becoming more accessible and reliable, driving the demand for effective treatments. Furthermore, continuous research in pharmaceutical development is leading to the creation of advanced therapeutic formulations designed to treat complex liver conditions more effectively. These improvements are contributing to broader treatment adoption and helping expand the market size.

By product, antiviral drugs emerged as the top-performing segment, accounting for USD 9.7 billion in 2024. The segment dominates due to the widespread occurrence of viral hepatitis, particularly hepatitis B and C, which remain among the leading causes of chronic liver damage and associated complications.

Direct-acting antiviral agents (DAAs) have significantly changed the treatment landscape by offering high cure rates and fewer side effects. These modern therapies are not only more effective but also easier for patients to complete, thanks to their shorter treatment durations. The launch of next-generation antivirals with better efficacy and safety profiles has accelerated global adoption, especially in regions with high infection burdens. Their proven ability to improve clinical outcomes continues to position this segment as a major contributor to overall market revenues.

In terms of disease type, the liver disease therapeutics market is classified into hepatitis, autoimmune disorders, non-alcoholic fatty liver disease (NAFLD), cancer, genetic conditions, and other categories. The hepatitis segment dominated the landscape with a substantial 47.4% share in 2024. This is largely due to the persistent global burden of hepatitis B and C infections, which continue to demand effective medical solutions.

Ongoing drug innovations have made treatment more accessible and efficient, with improved formulations offering shorter and safer therapeutic regimens. Modern treatments for hepatitis feature simplified dosing schedules and increased cure rates, resulting in improved patient adherence. In addition, continuous research to develop functional cures ensures that the hepatitis segment maintains its lead within the broader therapeutics market.

By gender, the market is divided into male and female groups. In 2024, the male population represented the dominant share and is expected to grow at a CAGR of 7.2%. This trend is driven by a higher incidence of liver conditions among men compared to women. Studies show that men are more frequently diagnosed with chronic liver diseases, including alcoholic liver disease, NAFLD, and hepatitis.

This gender disparity is also linked to biological and hormonal differences. Estrogen is thought to have a protective effect on liver tissue, making premenopausal women less likely to experience severe liver damage. Men, on the other hand, are more prone to disease progression from fatty liver to more serious conditions such as steatohepatitis and cirrhosis, which increases the demand for medical intervention in this demographic.

Regionally, the United States is the largest contributor to global revenues. The U.S. market was valued at USD 7.5 billion in 2021, USD 7.8 billion in 2022, USD 8.1 billion in 2023, and reached USD 8.5 billion in 2024. This consistent growth reflects a rising number of liver-related health issues, particularly non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH). Contributing factors include a surge in obesity, sedentary lifestyles, and associated metabolic disorders.

The healthcare system in the U.S. supports early diagnosis and access to high-cost specialty treatments through public and private insurance programs, which helps fuel continued market expansion. Increasing awareness, widespread screening efforts, and improved healthcare infrastructure all contribute to the country's leading position.

Globally, the competitive landscape features a mix of large multinational firms, regional companies, and emerging players. Approximately 45% to 50% of the market share is held by four leading companies that are actively engaged in expanding their market presence through collaborations, acquisitions, and the launch of innovative therapies. These companies are investing heavily in research and development to address unmet clinical needs and improve patient outcomes, giving them a strategic advantage in a rapidly growing industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Product
  • 2.2.3 Disease type
  • 2.2.4 Gender
  • 2.2.5 Route of administration
  • 2.2.6 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of liver diseases
    • 3.2.1.2 Advancements in diagnostic technologies
    • 3.2.1.3 Rise in sedentary lifestyles, poor diet, and alcohol use
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment, especially for biologics
    • 3.2.2.2 Side effects and limited efficacy of certain drugs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Strong R&D pipeline for nonalcoholic steatohepatitis (NASH) and liver cancer
    • 3.2.3.2 Expansion in emerging markets
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Antiviral drugs
• 5.3 Vaccines
• 5.4 Chemotherapy
• 5.5 Targeted therapy
• 5.6 Immunosuppressants
• 5.7 Immunoglobulins
• 5.8 Corticosteroids
• 5.9 Other products

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hepatitis
• 6.3 Autoimmune diseases
• 6.4 Non-alcoholic fatty liver disease (NAFLD)
• 6.5 Cancer
• 6.6 Genetic disorders
• 6.7 Other disease types

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Male
• 7.3 Female

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Parenteral

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals and clinics
• 9.3 Ambulatory surgical centers
• 9.4 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Amgen
• 11.2 AbbVie
• 11.3 Bristol-Myers Squibb
• 11.4 Bayer
• 11.5 GSK plc
• 11.6 Gilead Sciences
• 11.7 Hoffmann-La Roche
• 11.8 Intercept Pharmaceuticals
• 11.9 Johnson & Johnson Services
• 11.10 Merck & Co.
• 11.11 Novartis
• 11.12 Pfizer
• 11.13 Sanofi
• 11.14 Takeda Pharmaceutical Company Limited
• 11.15 Zydus Lifesciences